Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2005
05/17/2005US6893813 Methods for treatment of HIV and other infections using a T cell or viral activator and anti-retroviral combination therapy
05/17/2005US6893645 Process to make a sustained release formulation
05/17/2005US6893643 Comprises exogenous nucleotide sequences which encode exogenous amino acid sequences; infection of host cell with recombinant Yellow Fever Virus provides for expression of exogenous nucleic acid and production of antigen
05/17/2005US6893642 Anticancer nutraceutical from spirulina
05/17/2005US6893638 Methods for treating b cell lymphoma using CD80-specific antibodies
05/17/2005US6893637 Method of treating fibrosis
05/17/2005US6893636 Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
05/17/2005US6893635 Therapeutic treatment of upper respiratory infections using a nasal spray
05/17/2005US6893634 Without inflammatory or other immune response side effects; injection or implantation in tissue containing cancer growth; porous cellulose sulphate and polydimethyldiallylammonium membrane; breast and/or pancreatic tumors
05/17/2005US6893633 Methods and compositions for promoting the maturation of monocytes
05/17/2005US6893625 Mediating cytolysis; two light chains and two heavy chains; nonhuman variable region and human constant region; specifi-city for CD20 antigen bound by hybridoma HB9303 produced antibody
05/17/2005CA2486752A1 Process for the removal of porogens from temperature sensitive macroreticular polymers using steam at reduced pressure
05/17/2005CA2375673C Dna sequences derived from the genome of the papillomavirus hpv39, their application to in vitro diagnostic and to the production of immunogen compositions
05/17/2005CA2304987C Inhibition of an fgf-binding protein using ribozymes
05/17/2005CA2202390C Keratinocyte growth factor analogs
05/17/2005CA2182393C Dna mutagenesis by random fragmentation and reassembly
05/17/2005CA2115151C Tau/neurofilament protein kinases pk40 and pk36
05/12/2005WO2005043118A2 Drug discovery method
05/12/2005WO2005042777A2 App/ena antisense
05/12/2005WO2005042746A1 Bacterial virulence factors and uses thereof
05/12/2005WO2005042744A1 A recombinant protein with cancer suppression action, its encoding gene and use
05/12/2005WO2005042727A2 Methods of organ regeneration
05/12/2005WO2005042699A2 Modified polypeptides with therapeutic activity and methods of use
05/12/2005WO2005042698A2 T cell epitopes useful in a hepatitis c virus vaccine and as diagnostic tools and methods for identifying same
05/12/2005WO2005042583A1 Ec sod and cell transducing ec sod and use thereof
05/12/2005WO2005042576A1 Clq RELATED PROTEIN
05/12/2005WO2005042575A2 Method for down-regulation of vegf
05/12/2005WO2005042573A1 Modulation of the interaction of muc1 with muc1 ligands
05/12/2005WO2005042572A1 Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
05/12/2005WO2005042570A1 Hcv ns3-ns4a protease resistance mutants
05/12/2005WO2005042568A2 Hydrochloride salts of a glycopeptide phosphonate derivative
05/12/2005WO2005042567A1 Rapamycin peptides conjugates: synthesis and uses thereof
05/12/2005WO2005042566A2 Antiangiogenicpeptides for treating or preventing endometriosis
05/12/2005WO2005042565A2 Cyclin groove inhibitors
05/12/2005WO2005042560A2 Non-viral delivery of compounds to mitochondria
05/12/2005WO2005042531A1 Peptidomimetic compounds, stereoselective process for their preparation, their use as biologically active synthetic intermediates
05/12/2005WO2005042102A1 A protein involved in ovarian cancer
05/12/2005WO2005042048A2 Bioactive hydrogel compositions for regenerating connective tissue
05/12/2005WO2005042032A1 Methods for treating multiple sclerosis
05/12/2005WO2005042031A2 Oligoribonucleotides for the treatment of undesired skin and hair pigmentation due to rna interference
05/12/2005WO2005042027A2 Antagonists of the bradykinin b1 receptor
05/12/2005WO2005042024A1 Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
05/12/2005WO2005042020A2 Combinations for hcv treatment
05/12/2005WO2005042018A2 C-class oligonucleotide analogs with enhanced immunostimulatory potency
05/12/2005WO2005042012A1 Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
05/12/2005WO2005042011A1 Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
05/12/2005WO2005042010A1 Use of trefoil polypeptides in the treatment of diabetes
05/12/2005WO2005042009A1 Therapeutic regimens for baff antagonists
05/12/2005WO2005042008A1 Agent against malignant neuroglia and agent against malignant neuroglia for animals
05/12/2005WO2005042007A1 Antitumor agent
05/12/2005WO2005042006A2 Use of ephrins and related molecules to regulate cellular proliferation
05/12/2005WO2005042005A1 Amino acid composition with increased blood brain barrier permeability
05/12/2005WO2005042004A1 Use of transcription factor sox9 for the treatment of tumors expressing carcinoembryonnic antigen
05/12/2005WO2005042003A1 Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue
05/12/2005WO2005042002A2 Treatment of rhematoid arthritis with flip antagonists
05/12/2005WO2005042001A1 Anticancer peptide compositions
05/12/2005WO2005042000A1 Neuroprotective effects of gly-pro-glu following intravenous infusion
05/12/2005WO2005041999A1 Composition to enhance joint function and repair
05/12/2005WO2005041998A1 Peptide for promoting healing of fractures
05/12/2005WO2005041982A1 Combination therapy of peptide vaccination and estramustine treatment
05/12/2005WO2005041981A1 Combination therapy of peptide vaccination and estramustine treatment
05/12/2005WO2005041972A1 Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
05/12/2005WO2005041960A2 Neuromuscular blocking agents and antagonists thereof
05/12/2005WO2005041901A2 Therapeutics using somatostatin agonists
05/12/2005WO2005041898A2 Blood substitutes
05/12/2005WO2005041891A2 Neutrophil activation by immune response modifier compounds
05/12/2005WO2005041887A2 Pigment epithelium-derived factor, novel biological activity and methods of use
05/12/2005WO2005041882A2 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
05/12/2005WO2005041877A2 Method of inhibiting rejection following organ transplantation
05/12/2005WO2005041873A2 Formulation of exendin-4
05/12/2005WO2005041870A2 Composition and method for the treatment of eye disease
05/12/2005WO2005041866A2 Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes
05/12/2005WO2005041859A2 Conjugates and compositions for cellular delivery.
05/12/2005WO2005041852A2 Keratin gel and the types 2, 4 and 6 of collagens of frog protein
05/12/2005WO2005041756A2 Skin test for detecting non-allergic hypersensitivity
05/12/2005WO2005041631A2 Endotheliase-1 ligands
05/12/2005WO2005026207A3 Adipocyte complement related protein zacrp12
05/12/2005WO2005026192A3 Hpv cd8+ t-cell epitopes
05/12/2005WO2005010152A3 Human mast cell-expressed membrane protein
05/12/2005WO2005009948A3 Peptide inhibitors of beta-lactamases
05/12/2005WO2005007185A3 Formulation for a protein pharmaceutical without added human serum albumin (hsa)
05/12/2005WO2005007139A3 Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form
05/12/2005WO2005007072A3 Methods and pharmaceutical compositions for healing wounds
05/12/2005WO2005004804A3 Compositions and methods for selective dissolution of nascent intravascular blood clots
05/12/2005WO2005003164A3 Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases
05/12/2005WO2005000270A3 Inhalable formulations for treating pulmonary hypertension and methods of using same
05/12/2005WO2004111089A3 Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
05/12/2005WO2004108091A3 Antimicrobial flush solutions
05/12/2005WO2004103270A3 Compounds and methods for treatment of thrombosis
05/12/2005WO2004092339A3 Modulation of muc1 mediated signal transduction
05/12/2005WO2004091572A3 Cochleate compositions directed against expression of proteins
05/12/2005WO2004090120A3 Stem cells having increased sensitivity to sdf-1 and methods of generating and using same
05/12/2005WO2004084828A3 Keratinocyte-fibrocyte concomitant grafting for wound healing
05/12/2005WO2004082715A8 Concomitant drug as therapeutic agent for inflammatory bowel disease
05/12/2005WO2004078124A3 Methods and compositions involving mda-7
05/12/2005WO2004076631A3 Biologically active native biomatrix composition
05/12/2005WO2004067560A3 Herpes simplex vp16 protein binding polypeptides
05/12/2005WO2004037995A3 Methods for treating viral infection using il-28 and il-29
05/12/2005WO2004035605A3 Glycoprotein synthesis
05/12/2005WO2004029281A3 Methods and compositions for rnai mediated inhibition of viral gene expression in mammals
1 ... 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 ... 3163